Intelgenx Technologs
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral fil… Read more
Intelgenx Technologs (IGXT) - Total Assets
Latest total assets as of March 2024: $6.55 Million USD
Based on the latest financial reports, Intelgenx Technologs (IGXT) holds total assets worth $6.55 Million USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Intelgenx Technologs - Total Assets Trend (2006–2023)
This chart illustrates how Intelgenx Technologs’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Intelgenx Technologs - Asset Composition Analysis
Current Asset Composition (December 2023)
Intelgenx Technologs's total assets of $6.55 Million consist of 41.6% current assets and 58.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.6% |
| Accounts Receivable | $790.00K | 9.5% |
| Inventory | $71.00K | 0.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2023)
This chart illustrates how Intelgenx Technologs's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intelgenx Technologs's current assets represent 41.6% of total assets in 2023, a decrease from 75.1% in 2006.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2023, down from 35.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 9.5% of total assets.
Intelgenx Technologs Competitors by Total Assets
Key competitors of Intelgenx Technologs based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Intelgenx Technologs - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Intelgenx Technologs generates 0.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Intelgenx Technologs is currently not profitable relative to its asset base.
Intelgenx Technologs - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.13 | 0.45 | 3.33 |
| Quick Ratio | 0.12 | 0.45 | 3.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.44 Million | $ -6.19 Million | $ 5.59 Million |
Intelgenx Technologs - Advanced Valuation Insights
This section examines the relationship between Intelgenx Technologs's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.54 |
| Latest Market Cap to Assets Ratio | 2.78 |
| Asset Growth Rate (YoY) | -9.9% |
| Total Assets | $8.28 Million |
| Market Capitalization | $23.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Intelgenx Technologs's assets at a significant premium ( 2.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Intelgenx Technologs's assets decreased by 9.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Intelgenx Technologs (2006–2023)
The table below shows the annual total assets of Intelgenx Technologs from 2006 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $8.28 Million | -9.88% |
| 2022-12-31 | $9.19 Million | -48.67% |
| 2021-12-31 | $17.91 Million | +61.05% |
| 2020-12-31 | $11.12 Million | +0.89% |
| 2019-12-31 | $11.02 Million | -44.95% |
| 2018-12-31 | $20.02 Million | +52.26% |
| 2017-12-31 | $13.15 Million | +2.79% |
| 2016-12-31 | $12.79 Million | +43.45% |
| 2015-12-31 | $8.92 Million | +41.88% |
| 2014-12-31 | $6.28 Million | +1.08% |
| 2013-12-31 | $6.22 Million | +49.48% |
| 2012-12-31 | $4.16 Million | -8.99% |
| 2011-12-31 | $4.57 Million | +150.41% |
| 2010-12-31 | $1.82 Million | -36.22% |
| 2009-12-31 | $2.86 Million | +76.47% |
| 2008-12-31 | $1.62 Million | +27.56% |
| 2007-12-31 | $1.27 Million | +95.32% |
| 2006-12-31 | $650.84K | -- |